OPKO Announces Third Quarter Business Highlights and Diagnostic Sale Agreement
OPKO Health reports Q3 2026 business results and will sell its BioReference diagnostics operations to Labcorp for up to $872 million. The company also advanced its pipeline by dosing a new acromegaly drug and expanding its royalty financing.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed